{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:23:37Z","timestamp":1783488217834,"version":"3.55.0"},"publisher-location":"Cham","reference-count":134,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031803956","type":"print"},{"value":"9783031803963","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-80396-3_8","type":"book-chapter","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:59:36Z","timestamp":1742356776000},"page":"211-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pheochromocytoma in MEN2"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-2254","authenticated-orcid":false,"given":"Matti L.","family":"Gild","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimchi","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa H. M.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndal J.","family":"Tacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00423-011-0879-3","volume":"397","author":"G Agarwal","year":"2012","unstructured":"Agarwal G, Sadacharan D, Aggarwal V, Chand G, Mishra A, Agarwal A, Verma AK, Mishra SK (2012) Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series. Langenbeck\u2019s Arch Surg 397:1109\u20131116","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1210\/jc.2004-1398","volume":"90","author":"L Amar","year":"2005","unstructured":"Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF (2005) Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90:2110\u20132116","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12020-020-02332-2","volume":"69","author":"V Amodru","year":"2020","unstructured":"Amodru V, Taieb D, Guerin C, Romanet P, Paladino N, Brue T, Cuny T, Barlier A, Sebag F, Castinetti F (2020) MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine 69:496\u2013503","journal-title":"Endocrine"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archsurg.141.12.1199","volume":"141","author":"R Asari","year":"2006","unstructured":"Asari R, Scheuba C, Kaczirek K, Niederle B (2006) Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg 141:1199\u20131205. discussion 1205","journal-title":"Arch Surg"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118:2804\u20132812","journal-title":"Cancer"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2213-8587(20)30363-6","volume":"9","author":"I Bancos","year":"2021","unstructured":"Bancos I, Atkinson E, Eng C, Young WF Jr, Neumann HPH (2021) Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes Endocrinol 9:13\u201321","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1210\/jc.2005-1862","volume":"91","author":"DE Benn","year":"2006","unstructured":"Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O et al (2006) Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes. J Clin Endocrinol Metab 91:827\u2013836","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/biomedicines10081813","volume":"10","author":"C Bima","year":"2022","unstructured":"Bima C, Bioletto F, Lopez C, Bollati M, Arata S, Procopio M, Gesmundo I, Ghigo E, Maccario M, Parasiliti-Caprino M (2022) Clinical and pathological tools for predicting recurrence and\/or metastasis in patients with pheochromocytoma and paraganglioma. Biomedicines 10:1813","journal-title":"Biomedicines"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1210\/clinem\/dgz188","volume":"105","author":"E Buitenwerf","year":"2020","unstructured":"Buitenwerf E, Osinga TE, Timmers H, Lenders JWM, Feelders RA, Eekhoff EMW, Haak HR, Corssmit EPM, Bisschop P, Valk GD et al (2020) Efficacy of \u03b1-blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial. J Clin Endocrinol Metab 105:2381\u20132391","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1210\/jc.2018-01532","volume":"104","author":"L Canu","year":"2019","unstructured":"Canu L, Van Hemert JAW, Kerstens MN, Hartman RP, Khanna A, Kraljevic I, Kastelan D, Badiu C, Ambroziak U, Tabarin A et al (2019) CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab 104:312\u2013318","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","volume":"15","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Qi XP, Walz MK, Maia AL, Sans\u00f3 G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA et al (2014) Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 15:648\u2013655","journal-title":"Lancet Oncol"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12022-018-9534-7","volume":"29","author":"VKY Cheung","year":"2018","unstructured":"Cheung VKY, Gill AJ, Chou A (2018) Old, new, and emerging immunohistochemical markers in pheochromocytoma and paraganglioma. Endocr Pathol 29:169\u2013175","journal-title":"Endocr Pathol"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","volume":"164","author":"YY Cho","year":"2018","unstructured":"Cho YY, Kwak MK, Lee SE, Ahn SH, Kim H, Suh S, Kim BJ, Song KH, Koh JM, Kim JH et al (2018) A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score. Surgery 164:511\u2013517","journal-title":"Surgery"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/030089160509100110","volume":"91","author":"D Cotesta","year":"2005","unstructured":"Cotesta D, Caliumi C, Alo P, Petramala L, Reale MG, Masciangelo R, Signore A, Cianci R, D\u2019Erasmo E, Letizia C (2005) High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori 91:53\u201358","journal-title":"Tumori"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jama.1967.03130220058009","volume":"202","author":"RM Crago","year":"1967","unstructured":"Crago RM, Eckholdt JW, Wismell JG (1967) Pheochromocytoma. Treatment with alpha- and beta-adrenergic blocking drugs. JAMA 202:870\u2013874","journal-title":"JAMA"},{"key":"8_CR16","doi-asserted-by":"publisher","unstructured":"Crona J, Ta\u00efeb D, Pacak K (2017) New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 38(6):489\u2013515. https:\/\/doi.org\/10.1210\/er.2017-00062. PMID: 28938417; PMCID: PMC5716829","DOI":"10.1210\/er.2017-00062"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PL Dahia","year":"2014","unstructured":"Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14:108\u2013119","journal-title":"Nat Rev Cancer"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12020-017-1300-y","volume":"56","author":"R D\u00e4rr","year":"2017","unstructured":"D\u00e4rr R, Kuhn M, Bode C, Bornstein SR, Pacak K, Lenders JWM, Eisenhofer G (2017) Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine 56:495\u2013503","journal-title":"Endocrine"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/32.8.6146648","volume":"32","author":"RA DeLellis","year":"1984","unstructured":"DeLellis RA, Tischler AS, Wolfe HJ (1984) Multidirectional differentiation in neuroendocrine neoplasms. J Histochem Cytochem 32:899\u2013904","journal-title":"J Histochem Cytochem"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"dgae283","DOI":"10.1210\/clinem\/dgae283","volume":"2024","author":"B Deschler-Baier","year":"2024","unstructured":"Deschler-Baier B, Konda B, Massarelli E, Hu MI, Wirth LJ, Xu X, Wright J, Clifton-Bligh RJ (2024) Clinical activity of selpercatinib in RET-mutant pheochromocytoma. J Clin Endocrinol Metab 2024:dgae283. https:\/\/doi.org\/10.1210\/clinem\/dgae283","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/ejso.2002.1413","volume":"29","author":"E Edstrom Elder","year":"2003","unstructured":"Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B (2003) The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29:278\u2013283","journal-title":"Eur J Surg Oncol"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","volume":"60","author":"G Eisenhofer","year":"2014","unstructured":"Eisenhofer G, Peitzsch M (2014) Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem 60:1486\u20131499","journal-title":"Clin Chem"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00829","volume":"11","author":"G Eisenhofer","year":"2004","unstructured":"Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H et al (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423\u2013436","journal-title":"Endocr Relat Cancer"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","volume":"64","author":"G Eisenhofer","year":"2018","unstructured":"Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N, Langton K, Tsourdi E, P\u0119czkowska M, Fliedner S et al (2018) Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites. Clin Chem 64:1646\u20131656","journal-title":"Clin Chem"},{"key":"8_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100686","volume":"3","author":"CM Estrada-Zuniga","year":"2022","unstructured":"Estrada-Zuniga CM, Cheng ZM, Ethiraj P, Guo Q, Gonzalez-Cant\u00fa H, Adderley E, Lopez H, Landry BN, Zainal A, Aronin N et al (2022) A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions. Cell Rep Med 3:100686","journal-title":"Cell Rep Med"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2014","unstructured":"Favier J, Amar L, Gimenez-Roqueplo AP (2014) Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 11:101\u2013111","journal-title":"Nat Rev Endocrinol"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","volume":"50","author":"L Fishbein","year":"2021","unstructured":"Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA et al (2021) The North American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma. Pancreas 50:469\u2013493","journal-title":"Pancreas"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1196\/annals.1353.050","volume":"1073","author":"PA Fitzgerald","year":"2006","unstructured":"Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L et al (2006) Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 1073:465\u2013490","journal-title":"Ann N Y Acad Sci"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/BF01938677","volume":"103","author":"F Frankel","year":"1886","unstructured":"Frankel F (1886) Ein fall von doppelsetigen, vollig latent verlaufenen Nebenn ierentumor und zleichzeitizer Nephritis. Arch Pathol Anat Klin Med 103:244\u2013263","journal-title":"Arch Pathol Anat Klin Med"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1530\/eje.0.1350222","volume":"135","author":"K Frank-Raue","year":"1996","unstructured":"Frank-Raue K, Kratt T, Hoppner W, Buhr H, Ziegler R, Raue F (1996) Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 135:222\u2013225","journal-title":"Eur J Endocrinol"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12893-020-00824-6","volume":"20","author":"SQ Fu","year":"2020","unstructured":"Fu SQ, Wang SY, Chen Q, Liu YT, Li ZL, Sun T (2020) Laparoscopic versus open surgery for pheochromocytoma: a meta-analysis. BMC Surg 20:167","journal-title":"BMC Surg"},{"key":"8_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106779","volume":"104","author":"L Gan","year":"2022","unstructured":"Gan L, Meng C, Li K, Lei P, Li J, Wu J, Li Y (2022) Safety and effectiveness of minimally invasive adrenalectomy versus open adrenalectomy in patients with large adrenal tumors (\u22655 cm): a meta-analysis and systematic review. Int J Surg 104:106779","journal-title":"Int J Surg"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1097\/JS9.0000000000000389","volume":"109","author":"L Gan","year":"2023","unstructured":"Gan L, Peng L, Meng C, Zheng L, Zeng Z, Ge S, Wang Z, Li K, Li Y (2023) The role of laparoscopic adrenalectomy in the treatment of large pheochromocytomas (>6 cm): a meta-analysis and systematic review. Int J Surg 109:1459\u20131469","journal-title":"Int J Surg"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/cen.13737","volume":"89","author":"ML Gild","year":"2018","unstructured":"Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, Sywak M, Sidhu S, Delbridge LW, Robinson BG, Schembri G et al (2018) Role of DOTATATE-PET\/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol 89:139\u2013147","journal-title":"Clin Endocrinol"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-0031-1301302","volume":"44","author":"AP Gimenez-Roqueplo","year":"2012","unstructured":"Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44:328\u2013333","journal-title":"Horm Metab Res"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000074657","volume":"31","author":"O Gimm","year":"2004","unstructured":"Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP (2004) The genetic basis of pheochromocytoma. Front Horm Res 31:45\u201360","journal-title":"Front Horm Res"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","volume":"229","author":"RE Goldstein","year":"1999","unstructured":"Goldstein RE, O\u2019Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Oates JA, Brown N, Nadeau J, Smith B, Page DL et al (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755\u2013764; discussion 764-756","journal-title":"Ann Surg"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jamcollsurg.2012.10.012","volume":"216","author":"EG Grubbs","year":"2013","unstructured":"Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND (2013) Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 216:280\u2013289","journal-title":"J Am Coll Surg"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1210\/jc.2018-01707","volume":"104","author":"LM Gruber","year":"2019","unstructured":"Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, Young WF, Bancos I (2019) Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab 104:1386\u20131393","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2967\/jnumed.118.211706","volume":"60","author":"S Han","year":"2019","unstructured":"Han S, Suh CH, Woo S, Kim YJ, Lee JJ (2019) Performance of (68)Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med 60:369\u2013376","journal-title":"J Nucl Med"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2222010622","volume":"222","author":"S Hoegerle","year":"2002","unstructured":"Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP (2002) Pheochromocytomas: detection with 18F DOPA whole body PET\u2014initial results. Radiology 222:507\u2013512","journal-title":"Radiology"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WF, Hicks RJ (2015) Somatostatin receptor imaging with (68)Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500\u2013516","journal-title":"Radiographics"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T (2008) Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020\u20132028","journal-title":"Cancer"},{"key":"8_CR44","first-page":"1066","volume":"134","author":"M Iihara","year":"2003","unstructured":"Iihara M, Suzuki R, Kawamata A, Omi Y, Kodama H, Igari Y, Yamazaki K, Obara T (2003) Adrenal-preserving laparoscopic surgery in selected patients with bilateral adrenal tumors. Surgery (Oxf) 134:1066\u20131072. discussion 1072-1063","journal-title":"Surgery (Oxf)"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1210\/jc.2003-030235","volume":"88","author":"I Ilias","year":"2003","unstructured":"Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, McElroy B, Pacak K (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88:4083\u20134087","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1677\/ERC-07-0045","volume":"14","author":"I Ilias","year":"2007","unstructured":"Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K (2007) The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14:587\u2013599","journal-title":"Endocr Relat Cancer"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1530\/EJE-12-1106","volume":"168","author":"T Imai","year":"2013","unstructured":"Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, Sakurai A (2013) High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol 168:683\u2013687","journal-title":"Eur J Endocrinol"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s00330-008-1073-z","volume":"18","author":"AE Jacques","year":"2008","unstructured":"Jacques AE, Sahdev A, Sandrasagara M, Goldstein R, Berney D, Rockall AG, Chew S, Reznek RH (2008) Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 18:2885\u20132892","journal-title":"Eur Radiol"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","volume":"57","author":"S Jasim","year":"2017","unstructured":"Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC (2017) Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma. Endocrine 57:220\u2013225","journal-title":"Endocrine"},{"key":"8_CR1001","doi-asserted-by":"publisher","unstructured":"Jhawar S, Arakawa Y, Kumar S, Varghese D, Kim YS, Roper N, Elloumi F, Pommier Y, Pacak K, Del Rivero J (2022) New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications. Cancers (Basel) 14(3):594. https:\/\/doi.org\/10.3390\/cancers14030594. PMID: 35158861; PMCID: PMC8833412","DOI":"10.3390\/cancers14030594"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12893-020-0676-4","volume":"20","author":"YL Jiang","year":"2020","unstructured":"Jiang YL, Qian LJ, Li Z, Wang KE, Zhou XL, Zhou J, Ye CH (2020) Comparison of the retroperitoneal versus transperitoneal laparoscopic adrenalectomy perioperative outcomes and safety for pheochromocytoma: a meta-analysis. BMC Surg 20:12","journal-title":"BMC Surg"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"R239","DOI":"10.1530\/ERC-20-0043","volume":"27","author":"C Jimenez","year":"2020","unstructured":"Jimenez C, Fazeli S, Rom\u00e1n-Gonzalez A (2020a) Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer 27:R239\u2013R254","journal-title":"Endocr Relat Cancer"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.3390\/cancers12082307","volume":"12","author":"C Jimenez","year":"2020","unstructured":"Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA et al (2020b) Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas. Cancers (Basel) 12:2307","journal-title":"Cancers (Basel)"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1464-410X.1967.tb09801.x","volume":"39","author":"L Joseph","year":"1967","unstructured":"Joseph L (1967) Malignant phaeochromocytoma of the organ of Zuckerkandl with functioning metastases. Br J Urol 39:221\u2013225","journal-title":"Br J Urol"},{"key":"8_CR54","first-page":"23","volume":"33","author":"R Jovanovic","year":"2012","unstructured":"Jovanovic R, Kostadinova-Kunovska S, Bogoeva B, Spasevska L, Petrusevska G (2012) Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas. Prilozi 33:23\u201340","journal-title":"Prilozi"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1530\/ERC-17-0452","volume":"25","author":"M Kaczmarek-Ry\u015b","year":"2018","unstructured":"Kaczmarek-Ry\u015b M, Ziemnicka K, P\u0142awski A, Budny B, Michalak M, Hryhorowicz S, Hoppe-Go\u0142\u0119biewska J, Boru\u0144 P, Go\u0142\u0105b M, Czetwerty\u0144ska M et al (2018) Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course. Endocr Relat Cancer 25:421\u2013436","journal-title":"Endocr Relat Cancer"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000074658","volume":"31","author":"GA Kaltsas","year":"2004","unstructured":"Kaltsas GA, Papadogias D, Grossman AB (2004) The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 31:61\u201375","journal-title":"Front Horm Res"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0284185118764206","volume":"59","author":"Y Kan","year":"2018","unstructured":"Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z (2018) (68)Ga-somatostatin receptor analogs and (18)F-FDG PET\/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol 59:1466\u20131474","journal-title":"Acta Radiol"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"I18","DOI":"10.1161\/01.HYP.7.3_Pt_2.I18","volume":"7","author":"HR Keiser","year":"1985","unstructured":"Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD (1985) Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7:I18\u2013I24","journal-title":"Hypertension"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T et al (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405\u2013414","journal-title":"Endocr Relat Cancer"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/thy.2008.0403","volume":"19","author":"RT Kloos","year":"2009","unstructured":"Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565\u2013612","journal-title":"Thyroid"},{"key":"8_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, Hong SJ, Song DE, Lee SH (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12:e0187398","journal-title":"PLoS One"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5603\/EP.2016.0008","volume":"67","author":"A Kotecka-Blicharz","year":"2016","unstructured":"Kotecka-Blicharz A, Hasse-Lazar K, Jurecka-Lubieniecka B, Pawlaczek A, Oczko-Wojciechowska M, Bugajska B, Ledwon A, Kr\u00f3l A, Michalik B, Jarz\u0105b B (2016) Occurrence of phaeochromocytoma tumours in RET mutation carriers\u2014a single-centre study. Endokrynol Pol 67:54\u201358","journal-title":"Endokrynol Pol"},{"key":"8_CR63","first-page":"4438","volume":"7","author":"A Kurisaki-Arakawa","year":"2014","unstructured":"Kurisaki-Arakawa A, Saito T, Takahashi M, Mitani K, Yao T (2014) A case of (123)I-MIBG scintigram-negative functioning pheochromocytoma: immunohistochemical and molecular analysis with review of literature. Int J Clin Exp Pathol 7:4438\u20134447","journal-title":"Int J Clin Exp Pathol"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00000658-199306000-00001","volume":"217","author":"TC Lairmore","year":"1993","unstructured":"Lairmore TC, Ball DW, Baylin SB, Wells SA Jr (1993) Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 217:595\u2013601; discussion 601-593","journal-title":"Ann Surg"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1089\/thy.2016.0399","volume":"27","author":"M Lebeault","year":"2017","unstructured":"Lebeault M, Pinson S, Guillaud-Bataille M, Gimenez-Roqueplo AP, Carrie A, Barbu V, Pigny P, Bezieau S, Rey JM, Delvincourt C et al (2017) Nationwide French study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid 27:1511\u20131522","journal-title":"Thyroid"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1210\/jc.2009-1850","volume":"95","author":"JW Lenders","year":"2010","unstructured":"Lenders JW, Pacak K, Huynh TT, Sharabi Y, Mannelli M, Bratslavsky G, Goldstein DS, Bornstein SR, Eisenhofer G (2010) Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 95:238\u2013245","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915\u20131942","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00259-015-3003-z","volume":"42","author":"C Lepoutre-Lussey","year":"2015","unstructured":"Lepoutre-Lussey C, Caramella C, Bidault F, D\u00e9andreis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F et al (2015) Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET\/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging 42:868\u2013876","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/PAS.0000000000001768","volume":"45","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma J, Jimenez C, Zhang M (2021) Pheochromocytoma: a clinicopathologic and molecular study of 390 cases from a single center. Am J Surg Pathol 45:1155\u20131165","journal-title":"Am J Surg Pathol"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1245\/s10434-015-4519-y","volume":"22","author":"M Livingstone","year":"2015","unstructured":"Livingstone M, Duttchen K, Thompson J, Sunderani Z, Hawboldt G, Sarah Rose M, Pasieka J (2015) Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades. Ann Surg Oncol 22:4175\u20134180","journal-title":"Ann Surg Oncol"},{"key":"8_CR71","first-page":"134","volume":"57","author":"E Lopci","year":"2013","unstructured":"Lopci E, Zanoni L, Fanti S, Ambrosini V, Castellani MR, Aktolun C, Chiti A (2013) Gallium-68 DOTANOC imaging in paraganglioma\/pheochromocytoma: presentation of sample cases and review of the literature. Q J Nucl Med Mol Imaging 57:134\u2013145","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1353.001","volume":"1073","author":"WM Manger","year":"2006","unstructured":"Manger WM (2006) An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 1073:1\u201320","journal-title":"Ann N Y Acad Sci"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1196\/annals.1353.044","volume":"1073","author":"M Mannelli","year":"2006","unstructured":"Mannelli M (2006) Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073:405\u2013416","journal-title":"Ann N Y Acad Sci"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33:90\u2013114","journal-title":"Endocr Pathol"},{"key":"8_CR75","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, Pubul V, Percovich JC, Garcia-Burillo A, Hernando J, Arbizu J, Rode\u00f1o E, Estorch M et al (2023) Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging 50:2486\u20132500","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"509\u2013525","key":"8_CR76","first-page":"ix","volume":"21","author":"EA Mittendorf","year":"2007","unstructured":"Mittendorf EA, Evans DB, Lee JE, Perrier ND (2007) Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am 21(509\u2013525):ix","journal-title":"Hematol Oncol Clin North Am"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2796.1995.tb01211.x","volume":"238","author":"E Modigliani","year":"1995","unstructured":"Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L et al (1995) Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen study group. J Intern Med 238:363\u2013367","journal-title":"J Intern Med"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","volume":"17","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M (2010) Chromogranin A\u2014biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17:2427\u20132443","journal-title":"Ann Surg Oncol"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1210\/jc.2003-030262","volume":"88","author":"J Mundschenk","year":"2003","unstructured":"Mundschenk J, Unger N, Schulz S, Hollt V, Steinke R, Lehnert H (2003) Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88:5150\u20135157","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/PO.21.00127","volume":"5","author":"A Mweempwa","year":"2021","unstructured":"Mweempwa A, Xu H, Vissers JHA, Tothill RW, Pattison AD, Fellowes AP, Thomas DM, Richardson G, Hicks RJ, Grimmond SM et al (2021) Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma. JCO Precis Oncol 5:1160\u20131165","journal-title":"JCO Precis Oncol"},{"key":"8_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000347","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347","journal-title":"J Immunother Cancer"},{"key":"8_CR82","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HPH Neumann","year":"2002","unstructured":"Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459\u20131466","journal-title":"N Engl J Med"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa071407","volume":"357","author":"HP Neumann","year":"2007","unstructured":"Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A, Eng C (2007) Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 357:1311\u20131315","journal-title":"N Engl J Med"},{"key":"8_CR84","doi-asserted-by":"publisher","first-page":"T201","DOI":"10.1530\/ERC-18-0085","volume":"25","author":"HP Neumann","year":"2018","unstructured":"Neumann HP, Young WF, Krauss T, Bayley J-P, Schiavi F, Opocher G, Boedeker CC, Tirosh A, Castinetti F, Ruf J et al (2018) 65 YEARS OF THE DOUBLE HELIX: genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocr Relat Cancer 25:T201\u2013T219","journal-title":"Endocr Relat Cancer"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.7314\/APJCP.2014.15.4.1751","volume":"15","author":"I Ocal","year":"2014","unstructured":"Ocal I, Avci A, Cakalagaoglu F, Can H (2014) Lack of correlations among histopathological parameters, Ki-67 proliferation index and prognosis in pheochromocytoma patients. Asian Pac J Cancer Prev 15:1751\u20131755","journal-title":"Asian Pac J Cancer Prev"},{"key":"8_CR86","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, Krzyzanowska M, Reuther D, Chin S, Wang L et al (2019) A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120:1113\u20131119","journal-title":"Br J Cancer"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10689-004-6128-y","volume":"4","author":"G Opocher","year":"2005","unstructured":"Opocher G, Conton P, Schiavi F, Macino B, Mantero F (2005) Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer 4:13\u201316","journal-title":"Fam Cancer"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1210\/jc.2007-1720","volume":"92","author":"K Pacak","year":"2007","unstructured":"Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 92:4069\u20134079","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2796.2004.01425.x","volume":"257","author":"K Pacak","year":"2005","unstructured":"Pacak K, Ilias I, Adams KT, Eisenhofer G (2005) Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 257:60\u201368","journal-title":"J Intern Med"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"111","DOI":"10.14310\/horm.2002.1227","volume":"8","author":"K Pacak","year":"2009","unstructured":"Pacak K, Eisenhofer G, Ilias I (2009) Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens) 8:111\u2013116","journal-title":"Hormones (Athens)"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/jco.2015.33.7_suppl.457","volume":"33","author":"MEB Pichun","year":"2015","unstructured":"Pichun MEB, Edgerly M, Velarde M, Bates SE, Daerr R, Adams K, Pacak K, Fojo T (2015) Phase II clinical trial of axitinib in metastatic pheochromocytomas and paragangliomas (P\/PG): preliminary results. J Clin Oncol 33:457","journal-title":"J Clin Oncol"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","volume":"474","author":"C Pierre","year":"2019","unstructured":"Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, Pouget C, Nomine C, Lomazzi S, Vignaud JM, Weryha G et al (2019) COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch 474:721\u2013734","journal-title":"Virchows Arch"},{"key":"8_CR94","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/01.HYP.29.5.1133","volume":"29","author":"PF Plouin","year":"1997","unstructured":"Plouin PF, Chatellier G, Fofol I, Corvol P (1997) Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29:1133\u20131139","journal-title":"Hypertension"},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","volume":"174","author":"PF Plouin","year":"2016","unstructured":"Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JWM, Lussey-Lepoutre C, Steichen O (2016) European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174:G1\u2013G10","journal-title":"Eur J Endocrinol"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.surg.2007.09.013","volume":"142","author":"FJ Quayle","year":"2007","unstructured":"Quayle FJ, Fialkowski EA, Benveniste R, Moley JF (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800\u2013805; discussion 805.e801","journal-title":"Surgery"},{"key":"8_CR97","first-page":"1082","volume":"74","author":"JC Reubi","year":"1992","unstructured":"Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E, Lamberts S (1992) In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74:1082\u20131089","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s00268-008-9734-2","volume":"32","author":"JM Rodriguez","year":"2008","unstructured":"Rodriguez JM, Balsalobre M, Ponce JL, Rios A, Torregrosa NM, Tebar J, Parrilla P (2008) Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg 32:2520\u20132526","journal-title":"World J Surg"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/qjmed\/hcu208","volume":"108","author":"MA Rutherford","year":"2014","unstructured":"Rutherford MA, Rankin AJ, Yates TM, Mark PB, Perry CG, Reed NS, Freel EM (2014) Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. QJM 108:361\u2013368","journal-title":"QJM"},{"key":"8_CR100","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1097\/00000478-200111000-00010","volume":"25","author":"K Salmenkivi","year":"2001","unstructured":"Salmenkivi K, Haglund C, Arola J, Heikkila P (2001) Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 25:1419\u20131423","journal-title":"Am J Surg Pathol"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1210\/jc.2002-021251","volume":"88","author":"AM Sawka","year":"2003","unstructured":"Sawka AM, Jaeschke R, Singh RJ, Young WF Jr (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553\u2013558","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1002\/bjs.11348","volume":"107","author":"S Schimmack","year":"2020","unstructured":"Schimmack S, Kaiser J, Probst P, Kalkum E, Diener MK, Strobel O (2020) Meta-analysis of \u03b1-blockade versus no blockade before adrenalectomy for phaeochromocytoma. Br J Surg 107:e102\u2013e108","journal-title":"Br J Surg"},{"key":"8_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100171","volume":"6","author":"S Severi","year":"2021","unstructured":"Severi S, Bongiovanni A, Ferrara M, Nicolini S, Di Mauro F, Sansovini M, Lolli I, Tardelli E, Cittanti C, Di Iorio V et al (2021) Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open 6:100171","journal-title":"ESMO Open"},{"key":"8_CR104","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/archsurg.2010.159","volume":"145","author":"WT Shen","year":"2010","unstructured":"Shen WT, Grogan R, Vriens M, Clark OH, Duh QY (2010) One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg 145:893\u2013897","journal-title":"Arch Surg"},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/iju.13838","volume":"26","author":"K Shiraishi","year":"2019","unstructured":"Shiraishi K, Kitahara S, Ito H, Oba K, Ohmi C, Matsuyama H (2019) Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: comparative outcomes. Int J Urol 26:212\u2013216","journal-title":"Int J Urol"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2265.2006.02571.x","volume":"65","author":"L Sibal","year":"2006","unstructured":"Sibal L, Jovanovic A, Agarwal SC, Peaston RT, James RA, Lennard TW, Bliss R, Batchelor A, Perros P (2006) Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clin Endocrinol 65:186\u2013190","journal-title":"Clin Endocrinol"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/MNM.0000000000001251","volume":"41","author":"D Singh","year":"2020","unstructured":"Singh D, Shukla J, Walia R, Vatsa R, Paul N, Chhabra A, Nahar U, Singh H, Kumar R, Bhansali A et al (2020) Role of [68Ga]DOTANOC PET\/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study. Nucl Med Commun 41:1047\u20131059","journal-title":"Nucl Med Commun"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/cancers11020225","volume":"11","author":"A Stenman","year":"2019","unstructured":"Stenman A, Zedenius J, Juhlin CC (2019) The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-a meta-analysis and systematic review of the literature. Cancers (Basel) 11:225","journal-title":"Cancers (Basel)"},{"key":"8_CR109","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/cen.12513","volume":"81","author":"D Taieb","year":"2014","unstructured":"Taieb D, Kebebew E, Castinetti F, Chen CC, Henry JF, Pacak K (2014) Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clin Endocrinol 81:317\u2013328","journal-title":"Clin Endocrinol"},{"key":"8_CR110","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D et al (2019) European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46:2112\u20132137","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8_CR111","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","volume":"42","author":"M Takahashi","year":"1985","unstructured":"Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581\u2013588","journal-title":"Cell"},{"key":"8_CR112","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A (2013) Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 4:103\u2013110","journal-title":"Horm Cancer"},{"key":"8_CR1002","doi-asserted-by":"publisher","unstructured":"Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, Welander J, Tops CM, Firth H, Dwight T, Ercolino T, Mannelli M, Opocher G, Clifton-Bligh R, Gimm O, Maher ER, Robledo M, Gimenez-Roqueplo AP, Dahia PL (2017) NGS in PPGL (NGSnPPGL) Study Group Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol 13(4):233\u2013247. https:\/\/doi.org\/10.1038\/nrendo.2016.185. Epub 2016 Nov 18. PMID: 27857127","DOI":"10.1038\/nrendo.2016.185"},{"key":"8_CR113","doi-asserted-by":"publisher","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","volume":"98","author":"S Thosani","year":"2013","unstructured":"Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C (2013) The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 98:E1813\u2013E1819","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR114","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","volume":"25","author":"HJ Timmers","year":"2007","unstructured":"Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW, Pacak K (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25:2262\u20132269","journal-title":"J Clin Oncol"},{"key":"8_CR115","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jnci\/djs188","volume":"104","author":"HJ Timmers","year":"2012","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT et al (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 104:700\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"8_CR116","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/1754-9485.12620","volume":"61","author":"A Tiwari","year":"2017","unstructured":"Tiwari A, Shah N, Sarathi V, Malhotra G, Bakshi G, Prakash G, Khadilkar K, Pandit R, Lila A, Bandgar T (2017) Genetic status determines (18) F-FDG uptake in pheochromocytoma\/paraganglioma. J Med Imaging Radiat Oncol 61:745\u2013752","journal-title":"J Med Imaging Radiat Oncol"},{"key":"8_CR117","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/382080a0","volume":"382","author":"JJ Treanor","year":"1996","unstructured":"Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F et al (1996) Characterization of a multicomponent receptor for GDNF. Nature 382:80\u201383","journal-title":"Nature"},{"key":"8_CR118","first-page":"685","volume":"86","author":"E van der Harst","year":"2001","unstructured":"van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP et al (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685\u2013693","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR119","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers11070909","volume":"11","author":"AR Vyakaranam","year":"2019","unstructured":"Vyakaranam AR, Crona J, Norl\u00e9n O, Granberg D, Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss-Baron K, Thiis-Evensen E, Hellman P, Sundin A (2019) Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE. Cancers (Basel) 11:909","journal-title":"Cancers (Basel)"},{"key":"8_CR120","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12957-023-03164-w","volume":"21","author":"S Wan","year":"2023","unstructured":"Wan S, Li K, Wang C, Chen S, Wang H, Luo Y, Li X, Yang L (2023) Which surgical approach is more favorable for pheochromocytoma of different sizes (< 6 cm vs. \u2265 6 cm)? A single retrospective center experience. World J Surg Oncol 21:285","journal-title":"World J Surg Oncol"},{"key":"8_CR121","first-page":"769","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li M, Deng H, Pang Y, Liu L, Guan X (2020) The systems of metastatic potential prediction in pheochromocytoma and paraganglioma. Am J Cancer Res 10:769\u2013780","journal-title":"Am J Cancer Res"},{"key":"8_CR122","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1097\/JS9.0000000000000390","volume":"109","author":"J Wang","year":"2023","unstructured":"Wang J, Liu Q, Jiang S, Zhang J, He J, Li Y, Wang D (2023) Preoperative \u03b1-blockade versus no blockade for pheochromocytoma-paraganglioma patients undergoing surgery: a systematic review and updated meta-analysis. Int J Surg 109:1470\u20131480","journal-title":"Int J Surg"},{"key":"8_CR123","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1136\/bmj.1.6124.1395-a","volume":"1","author":"JD Wark","year":"1978","unstructured":"Wark JD, Larkins RG (1978) Pulmonary oedema after propranolol therapy in two cases of phaeochromocytoma. Br Med J 1:1395\u20131396","journal-title":"Br Med J"},{"key":"8_CR124","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-14-0730","volume":"172","author":"D Weismann","year":"2014","unstructured":"Weismann D, Peitzsch M, Raida A, Prejbisz A, Gosk M, Riester A, Willenberg HS, Klemm R, Manz G, Deutschbein T et al (2014) Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. Eur J Endocrinol 172:251\u2013260","journal-title":"Eur J Endocrinol"},{"key":"8_CR125","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1530\/ERC-11-0170","volume":"18","author":"J Welander","year":"2011","unstructured":"Welander J, Soderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18:R253\u2013R276","journal-title":"Endocr Relat Cancer"},{"key":"8_CR126","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee NY, Machens A, Moley JF, Pacini F et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567\u2013610","journal-title":"Thyroid"},{"key":"8_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-5347(17)37119-7","volume":"147","author":"RK Whalen","year":"1992","unstructured":"Whalen RK, Althausen AF, Daniels GH (1992) Extra-adrenal pheochromocytoma. J Urol 147:1\u201310","journal-title":"J Urol"},{"key":"8_CR128","first-page":"458","volume":"115","author":"BS Wilson","year":"1984","unstructured":"Wilson BS, Lloyd RV (1984) Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol 115:458\u2013468","journal-title":"Am J Pathol"},{"key":"8_CR129","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip L, Duh QY, Wachtel H, Jimenez C, Sturgeon C, Lee C, Vel\u00e1zquez-Fern\u00e1ndez D, Berber E, Hammer GD, Bancos I et al (2022) American Association of endocrine surgeons guidelines for adrenalectomy: executive summary. JAMA Surg 157:870\u2013877","journal-title":"JAMA Surg"},{"key":"8_CR130","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1530\/eje.0.1360028","volume":"136","author":"WF Young Jr","year":"1997","unstructured":"Young WF Jr (1997) Phaeochromocytoma: how to catch a moonbeam in your hand. Eur J Endocrinol 136:28\u201329","journal-title":"Eur J Endocrinol"},{"key":"8_CR131","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1530\/EJE-18-0901","volume":"181","author":"WT Zandee","year":"2019","unstructured":"Zandee WT, Feelders RA, Smit Duijzentkunst DA, Hofland J, Metselaar RM, Oldenburg RA, van Linge A, Kam BLR, Teunissen JJM, Korpershoek E et al (2019) Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol 181:45\u201353","journal-title":"Eur J Endocrinol"},{"key":"8_CR132","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s13304-023-01475-x","volume":"75","author":"QB Zhang","year":"2023","unstructured":"Zhang QB, Huang YS, Yan L, Liu Z, Xu ZH, Gu GL (2023) Comparison of lateral transperitoneal versus retroperitoneal laparoscopic adrenalectomy for pheochromocytoma: a single-centre retrospective study. Updat Surg 75:1259\u20131266","journal-title":"Updat Surg"},{"key":"8_CR133","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.eprac.2022.06.013","volume":"28","author":"CY Zhu","year":"2022","unstructured":"Zhu CY, Hong JC, Kamdar NV, Hu MY, Tseng CH, Lee JS, Kuo EJ, Yu R, Isorena J, Yeh MW et al (2022) Comparison of preoperative alpha-blockade for resection of paraganglioma and pheochromocytoma. Endocr Pract 28:889\u2013896","journal-title":"Endocr Pract"}],"container-title":["Recent Results in Cancer Research","Medullary Thyroid Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-80396-3_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:32:19Z","timestamp":1742358739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-80396-3_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031803956","9783031803963"],"references-count":134,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-80396-3_8","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"20 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}